CAS: 75336-86-6; (R)-2-Methylpiperazine

相似化合物

120737-59-9 147081-29-6 163765-44-4

上下游产品

CAS号126458-16-0 (R)-2-HYDROXYME... | CAS号132871-11-5 1-苄基-3(R)-甲基哌嗪 | CAS号24955-56-4 Z-Gly-D-Ala-OMe | CAS号132871-09-1 1-苄基-3-甲基-哌嗪-2,5-二酮 | CAS号88547-15-3 2,5-Piperazined... | CAS号107-21-1 乙二醇 | CAS号357263-13-9 1-[(2R)-4-苯甲酰基-... | CAS号393513-95-6 (3R)-1-(3-氯吡啶-2... | CAS号313657-75-9 (R)-3-甲基-1-三苯甲基哌嗪 | CAS号357262-90-9 4-苯甲酰基-2-甲基-1-[... | CAS号357263-39-9 (R)-2-甲基-4-苯甲酰基哌嗪 | CAS号313657-76-0 (R)-2-氯-3-(2-甲基... | CAS号132871-11-5 1-苄基-3(R)-甲基哌嗪 | CAS号623586-00-5 (R)-4-Cbz-2-甲基哌嗪 | CAS号163765-44-4 (R)-1-B°C-3-甲基哌嗪 | CAS号1201670-92-9 (R)-4-(3-甲基哌嗪-1...

2-甲基哌嗪置于sodium Hydroxide体系中,用 Branched octane,乙醇,水 作为反应溶剂,化学反应 4.0H,反应生成 (R)-(-)-2-甲基哌嗪
参考文献: Novel Process[fr] Nouveau Procede
标题: Novel Process[fr] Nouveau Procede
摘要:本发明涉及一种用于制备在中枢神经系统中具有治疗活性的化合物的过程.在一个方面,本发明涉及一种制备通式(i)化合物的过程.本发明还涉及(2R)-1-(3-氯-2-吡啶基)-2-甲基哌嗪盐酸盐及其制备方法.本发明的另一个目的是一种通式(i)化合物.本发明的另一个目的是一种用于治疗或预防与5-羟色胺相关的疾病的方法,包括向需要的受试者施用上述化合物的有效量;以及利用该化合物制造用于治疗5-羟色胺相关疾病的药物.

专利信息

专利号:US-11708320-B2
优先权日:2018-06-29
标 题:Environmentally-friendly hydroazidation of olefins
发明人：XU HAO
权利人:UNIV GEORGIA STATE RES FOUND
摘要:The present invention provides processes for the synthesis of organic azides, intermediates for the production thereof, and compositions related thereto.

专利号:CN-1629146-A
优先权日:2003-12-19
标题 :Process for synthesis of chiral 2-substituted piperazine and its derivatives

专利号:EP-0754686-B1
优先权日:1995-07-19
标 题 :2-cyanopiperazine and use thereof for the synthesis of biologically active substances

专利号:US-6245773-B1
优先权日:1996-05-16
标题:5-(heterocyclic alkyl)-6-aryl-dihydropyrimidines
发明人：WONG WAI C; LAGU BHARAT; NAGARATHNAM DHANAPALAN; MARZABADI MOHAMMAD R; GLUCHOWSKI CHARLES
权利人:SYNAPTIC PHARMA CORP
摘要:This invention is directed to dihydropyrimidine compounds of the following formula: n which are selective antagonists for human α 1A receptors. This invention is also related to uses of these compounds for lowering intraocular pressure, inhibiting cholesterol synthesis, relaxing lower urinary tract tissue, the treatment of benign prostatic hyperplasia, impotency, cardiac arrhythmia and for the treatment of any disease where antagonism of the α 1A receptor may be useful. The invention further provides a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier.